Syndax pauses entinostat-PD-1/PD-L1 combo program

Syndax said in its 4Q18 financial results that it will "defer advancement" of its program evaluating entinostat plus PD-1/PD-L1 inhibitors after the combinations missed the primary endpoints of improving

Read the full 297 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE